• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Medtech outlook 2013: Major environmental factors for the year ahead

Medtech outlook 2013: Major environmental factors for the year ahead

January 4, 2013 By MassDevice staff

rising and falling illustration

Wall Street analysts released their predictions for the major medical device industry trends of 2013, and the outlook isn’t much to celebrate.

In a report released late last year Leerink Swann analysts outlined a handful of predictions for 2013, generally projecting dampened sales growth and enduring, if not increasing, pricing and reimbursement pressures as frugality continues to drive healthcare.

"Today medtech companies face maturing end-markets, ongoing macroeconomic challenges, and a changing healthcare environment – all of which are likely to pressure growth acceleration prospects broadly speaking," analysts Danielle Antalffy and Richard Newitter wrote.

Challenges in the U.S. economic climate may spur an increase in medtech M&A activity, they added, and investors will look for companies with "exposure to new product cycles and/or faster-growing end-user markets," they added.

This year will also likely see more restructuring efforts and device makers cope with the medical device tax, and perhaps a stronger push into emerging markets in order to make up for the sluggish environment in developed markets.

The Swann analysts broke down their 2013 predictions into 9 parts:

  1. "Top-line growth acceleration in large-cap medtech likely muted" – That means about 3% sales growth for large-cap companies, with the exception of companies like Edwards Lifesciences (NYSE:EW) and Intuitive Surgical (NSDQ:ISRG). Those companies are operating in the transcatheter aortic valve and robot-assisted surgery segments, which the Swann analysts pegged as ones with faster-growing end-user markets.
  2. "More restructuring and op-ex cuts likely in an effort to offset the medtech tax" – Despite the industry’s best efforts device makers will start making their 1st device tax payments as early as this month, and they’re likely to have a hard time passing on that cost to customers given hospitals’ focus on driving down healthcare costs. Large-cap companies may turn to operational cuts, such as layoffs, in order to offset the new cost.
  3. “small-cap medtech path to profitability likely lengthened” – Smaller companies will generally have a tougher time absorbing the new medical device tax, meaning a longer road to profitability and possibly higher interest in selling to a larger company.
  4. “Industry price/volume/reimbursement pressures unlikely to dissipate and could even intensify” – Major medtech hurdles aren’t going anywhere in 2013, including economic turmoil in Europe, reimbursement pressure, high unemployment and related lack of access to healthcare and more physicians joining hospital groups in order to gain bargaining leverage. Other environmental factors may even get worse, such as the new Medicare cuts included in the fiscal cliff deal, a new Medicare bundled payment imitative that may favor older and cheaper devices, growing price and volume pressures as Accountable Care Organizations look for ways to trim costs from healthcare and a possible increase in scrutiny on procedures deemed controversial or unnecessary.
  5. “Further expansion into faster-growth emerging markets necessary to
    counter slowing growth trends in developed markets”
    – A significant portion of large medtech companies derive between 40%-60% of their revenue from markets outside the U.S., including from the so-called "BRIC" countries of Brazil, Russia, India and China, and those percentages are likely to grow in 2013. This year will likely see more overseas M&A and other measures designed to gain a foothold in emerging markets, including devices tailored to meet local technology and pricing needs.
  6. “Cardiology pricing and procedures likely still under pressure” – The cardiology slump, a major feature of the U.S. healthcare market for the past several years, will keep right on slumping. 2013 will see more declines in the large cardiology markets in the U.S., such as cardiac rhythm management devices and drug-eluting stents. Overseas cardiology markets may make a turnaround from last year’s slide to sees some modest growth this year.
  7. “In orthopedics, at best we expect stable price/volume trends” – The orthopedics market looks to be stagnant for this year as downward pricing pressures look to negate modest volume growth. The orthopedics extremities segment may see above-average growth, but pressure on spinal devices will keep that segment from making any "significant" moves in the next year. Some growth opportunities do exist, such as for MIS spine procedures, and smaller spine companies are poised to continue taking share from the big dogs.
  8. “Higher payout ratios likely on tap” – Device makers this year will likely focus on handing large sums back to shareholders as investors seem to be leaning toward companies with buyback and dividend plans rather than those that put their money back into their business. M&A activity is poised to be the top cash draw for large-cap device makers, but more companies may shift to higher payout strategies.
  9. “‘High growth’ medtech market opportunities are scarce … but ones that
    remain should continue to draw increasing levels of investor attention”
    – Top areas of interest in 2013 include transcatheter valves, left ventricular assist devices, cervical discs, renal denervation and robotics.

Filed Under: News Well, Wall Street Beat Tagged With: Leerink Partners

In case you missed it

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Dyad Medical wins FDA clearance for cardiac imaging platform Echo:Prio
  • Outset Medical wins national VA contract
  • Inspire Medical Systems appoints former Zimmer Biomet exec as VP of investor relations
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results
  • ResMed expects steady growth over the next year
  • Ambu is letting go of 200 employees
  • Medtronic has Class I recall for low-shock risk in ICDs
  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy

RSS From Medical Design & Outsourcing

  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy